Transfusion Medicine Reviews最新文献

{"title":"Transfusion Medicine in the 21st Century: Beyond Rebalancing the Humors","authors":"Krystalyn E. Hudson , James C. Zimring","doi":"10.1016/j.tmrv.2022.09.003","DOIUrl":"10.1016/j.tmrv.2022.09.003","url":null,"abstract":"","PeriodicalId":56081,"journal":{"name":"Transfusion Medicine Reviews","volume":"36 4","pages":"Pages 173-174"},"PeriodicalIF":4.5,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10397106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma Cell Directed Therapy for Immune Thrombotic Thrombocytopenic Purpura (iTTP)","authors":"Melissa Chen ,&nbsp;Jake Shortt","doi":"10.1016/j.tmrv.2022.09.001","DOIUrl":"10.1016/j.tmrv.2022.09.001","url":null,"abstract":"<div><p><span>Immune thrombotic thrombocytopenic purpura (iTTP) is a microangiopathic hemolytic anemia (MAHA) underpinned by autoreactivity against the von Willebrand factor (vWF) cleaving protease, ADAMTS13 (</span><u>a</u> <u>d</u>isintegrin <u>a</u>nd <u>m</u>etalloproteinase with a <u>t</u>hrombo<u>s</u>pondin type 1 motif, member <u>13</u>). Autoantibody mediated ADAMTS13 inhibition leads to the accumulation of ultra-large vWF multimers which activate platelets and endothelium to initiate microvascular thrombosis. In the absence of urgent therapeutic intervention, iTTP is rapidly fatal due to cumulative organ dysfunction including catastrophic neurological and cardiac sequalae. Therapeutic plasma exchange (TPE) is the mainstay of initial therapy and aims to remove pathological autoantibodies and ultra-large vWF multimers while replenishing ADAMTS13. Immunosuppression is an important treatment adjunct, as attainment of remission and successful TPE cessation is strongly associated with suppression of anti-ADAMTS13 antibody production. More recently, caplacizumab, an antibody fragment blocking the interaction between vWF multimers and platelets, has been incorporated into acute TTP management to mitigate end-organ damage while awaiting suppression of anti-ADAMTS13 activity. In most cases, remission is achieved using corticosteroids alone or in combination with the B-cell depleting antibody, rituximab. However, some patients are refractory to front-line immunosuppression in the context of ‘inhibitor boosting’ whereby the exposure to homologous plasma exacerbates the underlying autoimmune flare. As such cases have been observed in the context of likely effective B-cell depletion, it has been hypothesized that plasma cells (ie, terminally differentiated B-cells) may provide a therapy-resistant nidus of anti-ADAMTS13 production as has been demonstrated in other autoimmune disease settings. Autoreactive plasma cells can be targeted by conventional and novel therapeutics, including those developed for malignant plasma cells in the context of multiple myeloma. Here we review the rationale and evidence for plasma cell directed therapy in refractory iTTP, with a focus on the proteasome inhibitor, bortezomib, and the CD38 monoclonal antibody, daratumumab.</p></div>","PeriodicalId":56081,"journal":{"name":"Transfusion Medicine Reviews","volume":"36 4","pages":"Pages 204-214"},"PeriodicalIF":4.5,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10747123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reflections of Dr. Morris Blajchman (1940-2022)","authors":"","doi":"10.1016/j.tmrv.2022.06.002","DOIUrl":"10.1016/j.tmrv.2022.06.002","url":null,"abstract":"","PeriodicalId":56081,"journal":{"name":"Transfusion Medicine Reviews","volume":"36 3","pages":"Pages 115-116"},"PeriodicalIF":4.5,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0887796322000207/pdfft?md5=5beb61e50f21f07f6a0ce51ccf414509&pid=1-s2.0-S0887796322000207-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46205342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Journal Club","authors":"","doi":"10.1016/j.tmrv.2022.06.005","DOIUrl":"https://doi.org/10.1016/j.tmrv.2022.06.005","url":null,"abstract":"","PeriodicalId":56081,"journal":{"name":"Transfusion Medicine Reviews","volume":"36 3","pages":"Pages 165-172"},"PeriodicalIF":4.5,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136472894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AABB's response to ‘Gender Inequities in Transfusion Medicine Society Recognition Awards’","authors":"Jay Lewis","doi":"10.1016/j.tmrv.2022.06.006","DOIUrl":"10.1016/j.tmrv.2022.06.006","url":null,"abstract":"","PeriodicalId":56081,"journal":{"name":"Transfusion Medicine Reviews","volume":"36 3","pages":"Page 164"},"PeriodicalIF":4.5,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40646933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins Against SARS-CoV-2","authors":"Thierry Burnouf ,&nbsp;Birgit Gathof ,&nbsp;Evan M. Bloch ,&nbsp;Renée Bazin ,&nbsp;Vincenzo de Angelis ,&nbsp;Gopal Kumar Patidar ,&nbsp;Rada M. Grubovic Rastvorceva ,&nbsp;Adaeze Oreh ,&nbsp;Ruchika Goel ,&nbsp;Naomi Rahimi-Levene ,&nbsp;Salwa Hindawi ,&nbsp;Arwa Z. Al-Riyami ,&nbsp;Cynthia So-Osman ,&nbsp;ISBT COVID-19 Convalescent Plasma Working Group (see the Appendix)","doi":"10.1016/j.tmrv.2022.06.001","DOIUrl":"10.1016/j.tmrv.2022.06.001","url":null,"abstract":"<div><p>The coronavirus disease 2019 (COVID-19) pandemic has highlighted the potential therapeutic value of early passive polyclonal immunotherapy using high-titer convalescent plasma (CCP). Human polyclonal hyperimmune immunoglobulin (HIG) has several advantages over CCP. Unlike CCP, HIG can provide standardized and controlled antibody content. It is also subjected to robust pathogen reduction rendering it virally safe and is purified by technologies demonstrated to preserve immunoglobulin neutralization capacity and Fc fragment integrity. This document provides an overview of current practices and guidance for the collection and testing of plasma rich in antibodies against Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) and its industrial fractionation for the manufacture of quality-assured and safe HIG. Considerations are also given to the production of HIG preparations in low- and middle-income countries.</p></div>","PeriodicalId":56081,"journal":{"name":"Transfusion Medicine Reviews","volume":"36 3","pages":"Pages 125-132"},"PeriodicalIF":4.5,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9183240/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10387306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Home Delivery: Transfusion Services When and Where They Are Needed","authors":"Briony Shaw ,&nbsp;Erica M. Wood ,&nbsp;Jeannie Callum ,&nbsp;Zoe K. McQuilten","doi":"10.1016/j.tmrv.2022.06.003","DOIUrl":"10.1016/j.tmrv.2022.06.003","url":null,"abstract":"<div><p>Home blood product transfusion has been utilized around the world in various forms over the past few decades. There is current interest in decentralizing hospital care to improve patient independence and convenience, minimize cost to the health service, and to prevent nosocomial infection, especially with the recent COVID-19 pandemic. The transition to “hospital in the home” is occurring across the healthcare sector driven by aims to improve patient outcomes and patient satisfaction, capacity pressures in the acute care sector, and most recently due to concerns regarding infectious disease transmission in hospital settings. This review explores the published literature on home red cell and platelet transfusions, and where the literature is limited, also considered data from subcutaneous immunoglobulin studies. Current published experience on red cell and platelet transfusion at home has identified benefits to the patient and health service, with further studies needed to quantify improvement in quality of life and health-related outcomes. Safety concerns may be a perceived barrier to implementation of home transfusion, however current published data suggests serious adverse reactions are rare. Cost-effectiveness data for home transfusion are very limited and a key area for future research. Home transfusion has the potential to benefit from newer technologies, such as portable/remote monitoring and electronic patient identifiers.</p></div>","PeriodicalId":56081,"journal":{"name":"Transfusion Medicine Reviews","volume":"36 3","pages":"Pages 117-124"},"PeriodicalIF":4.5,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40565686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Actions and Attitudes of Men who Have Sex With Men Under Past, Current, and Hypothetical Future Blood Donation Deferral Policies","authors":"Christopher N. Johns ,&nbsp;Grant Simonson ,&nbsp;Benny Mart Hiwatig ,&nbsp;Michael W. Ross","doi":"10.1016/j.tmrv.2022.06.007","DOIUrl":"10.1016/j.tmrv.2022.06.007","url":null,"abstract":"<div><p>Eligibility criteria for blood product donation are important for the safety of the blood supply, though many have called into question criteria that limit donations for men-who-have-sex-with-men (MSM). Recently, in the U.S.A., the Food and Drug Administration (FDA), decreased the ‘deferral’ period, the period in which one must abstain from sex, for MSM, from twelve months to three. This study examined the proportion of MSM respondents that donated blood under past and current deferral policies, as well as the proportion that would consider donating under hypothetical shorter deferral policies. To achieve this, an electronic survey was disseminated on social media platforms via virtual flier calling for participation from a self-selected convenience sample of the MSM community. Compared to either the 12-month or 3-month deferral policies, intent to donate blood was significantly higher in both alternative two week or no deferral policy scenarios. The majority of respondents who did donate did so without following deferral guidelines under both the 12-month and 3-month policies. There was no significant change in the proportion of those who donated against guidelines between the twelve- and three-month deferrals. While social media is an effective tool for survey work it poses significant risk for selection bias. Further studies with diverse sampling are necessary to better elucidate blood production donation trends within the MSM community.</p></div>","PeriodicalId":56081,"journal":{"name":"Transfusion Medicine Reviews","volume":"36 3","pages":"Pages 152-158"},"PeriodicalIF":4.5,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40671282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison Between Standard and High Dose of G-CSF for Mobilization of Hematopoietic Progenitors Cells in Patients and Healthy Donors","authors":"Irene García-García ,&nbsp;Joan Cid ,&nbsp;Gloria Carbassé ,&nbsp;Javier López-Jiménez ,&nbsp;Gemma Moreno ,&nbsp;Miquel Lozano","doi":"10.1016/j.tmrv.2022.06.004","DOIUrl":"10.1016/j.tmrv.2022.06.004","url":null,"abstract":"<div><p>A standard dose of 10 µg/kg/day granulocyte colony stimulating factors (G-CSF) is currently recommended for hematopoietic progenitor cells (HPCs) mobilization. Our aim was to analyze whether certain patients or healthy donors could benefit from high dose of G-CSF.We performed a retrospective multicenter analysis of HPCs mobilization procedures (2015-2020) in patients and healthy donors. Those who received standard dose of G-CSF (10 µg/Kg/day for 4 days to patients and healthy donors) and those that received higher dose (24 µg/Kg/day for 4 days to patients and 16 µg/Kg/day for 4 days to healthy donors) were compared.496 individuals were included (201 standard dose and 295 higher dose). Between standard or higher dose, we did not find significant differences in median number of mobilized CD34+ cells/mL, neither among healthy donors (77 100 vs 75 500 respectively, <em>P</em> = .895), nor in patients (34 270 vs 33 704 respectively, <em>P</em> = .584). Additionally, among those with the same underlaying pathology the comparison between standard and higher dose did not showed differences. High G-CSF dose was not associated with a less frequent incidence of poor mobilizers (&lt;20 000 CD34+ cells/mL) neither in healthy donors (1 [1.3%] vs 0; <em>P</em> = .218) nor patients (30 [24.4%] vs 32 [18.1%]; <em>P</em> = .165). Multivariate analysis showed that age, gender, and G-CSF dose did not influence median number of mobilized CD34+ cells/mL in healthy donors or patients. However, the underlying pathology among patients significantly influenced the CD34+ cells mobilization. In healthy donors, cellular blood count showed significantly higher leukocytes and platelets count with G-CSF high-dose, while in patients just a higher platelets count was found. To conclude, high dose of G-CSF compared to standard dose did not show significant benefit in terms of mobilization of CD34+ cells in healthy donors or in patients, also without a decrease in the incidence of poor mobilizers.</p></div>","PeriodicalId":56081,"journal":{"name":"Transfusion Medicine Reviews","volume":"36 3","pages":"Pages 159-163"},"PeriodicalIF":4.5,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40597568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hyperkalaemia Following Blood Transfusion–a Systematic Review Assessing Evidence and Risks","authors":"Julia Wolf ,&nbsp;Louise J. Geneen ,&nbsp;Athina Meli ,&nbsp;Carolyn Doree ,&nbsp;Rebecca Cardigan ,&nbsp;Helen V. New","doi":"10.1016/j.tmrv.2022.04.003","DOIUrl":"10.1016/j.tmrv.2022.04.003","url":null,"abstract":"<div><p>Hyperkalaemia following transfusion is widely reported in the literature. Our objective was to critically review recent evidence on hyperkalaemia in association with transfusion and to assess whether specific aspects of transfusion practice can affect the likelihood of developing hyperkalaemia. We searched 9 electronic databases (including MEDLINE, Embase, and Transfusion Evidence Library) using a predefined search strategy, from 2010 to April 8, 2021. Three reviewers performed dual screening, extraction, and risk of bias assessment. We used Cochrane risk of bias (ROB) 2 for assessment of RCTs, ROBINS-I for non-RCTs, and GRADE to assess the certainty of the evidence. We report 7 comparisons of interest in <em>n</em> = 3729 patients from 28 studies (11 RCTs, 4 prospective cohort studies, and 13 retrospective cohort studies): (1) age of blood, (2) washing, (3) filtration, (4) irradiation, (5) fluid type, (6) transfusion vs no transfusion, (7) blood volume/rate. Of the 28 studies included, 25 reported outcomes of potassium (K+) concentration, 17 the number developing hyperkalaemia, 13 mortality, 10 cardiac arrest, and 10 cardiac arrhythmia. Only 16 studies provided analysable data suitable for quantitative analysis. Evidence addressing our outcomes was of very low certainty (downgraded for incomplete outcome data, baseline imbalance, imprecision around the estimate, and small sample size). While 5 studies showed a difference in K+ concentration up to 6 hours posttransfusion for 3 comparisons (age of blood, washing, and transfusion volume/rate), and 3 studies showed a difference in the diagnosis of hyperkalaemia for 2 comparisons (age of blood, and transfusion volume/rate), the evidence was inconsistent across all included studies. There was no difference in any reported outcomes for 4 comparisons (filtration, irradiation, fluid type, or transfusion vs no transfusion). Overall, the reported evidence was too weak to support identification of groups most at risk of hyperkalaemia or to support recommendations on use of short-storage RBC. For other commonly used risk mitigations for hyperkalaemia in transfusion medicine, the (low certainty) evidence was either conflicting or not supportive.</p></div>","PeriodicalId":56081,"journal":{"name":"Transfusion Medicine Reviews","volume":"36 3","pages":"Pages 133-142"},"PeriodicalIF":4.5,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45809396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}